We offer a robust portfolio of tests, including:

IBD sgi Diagnostic®: Combines serologic, genetic and inflammation markers to help differentiate IBD vs non-IBD and ulcerative colitis vs Crohn’s disease while offering risk stratification of disease phenotypes.

Respondr®: A recently launched precision medicine tool that incorporates pre-therapy clearance and genetic risk to indicate a patient’s likelihood of response to infliximab, adalimumab or their biosimilars to help guide therapeutic selection and management prior to initiation of therapy.

PredictrPK®: The only tests to offer personalized dosing optimization strategies for infliximab, adalimumab and their respective biosimilars in support of sustained clinical remission, drug persistence and improved outcomes. PredictrPK uniquely analyzes your patient’s unique pharmacokinetics to calculate drug clearance, which may change prior to drug levels and be an early predictor of immunogenicity, disease relapse and lack of clinical response. Tests for vedolizumab and ustekinumab are coming soon.

Monitr®: The first non-invasive serum test to support assessment and monitoring of endoscopic disease activity in Crohn’s Disease patients.

Anser®: Drug-tolerant therapeutic drug monitoring tests that measure serum drug levels and anti-drug antibodies for infliximab, adalimumab, vedolizumab, ustekinumab and their respective biosimilars. New to the Anser menu, risankizumab.